文献速递消化系统肿瘤

德曲妥珠单抗治疗HER2阳性晚期结直肠癌患者(DESTINY-CRC02):多中心、随机、2期试验主要结果

Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2024-08-05

DESTINY-CRC02是一项多中心、随机、两阶段、两臂2期研究,评估德曲妥珠单抗5.4 mg/kg与6.4 mg/kg在经治HER2阳性、RAS野生型或突变型转移性结直肠癌患者中的疗效与安全性。5.4 mg/kg组确认客观缓解率为37.8%(31/82,95%CI 27.3-49.2),6.4 mg/kg组为27.5%(11/40,95%CI 14.6-43.9)。作者认为5.4 mg/kg的 promising 抗肿瘤活性和有利安全性支持其作为经治HER2阳性转移性结直肠癌的最佳单药剂量。

要点

  • 5.4 mg/kg组确认客观缓解率37.8%(31/82,95%CI 27.3-49.2),6.4 mg/kg组为27.5%(11/40,95%CI 14.6-43.9)。
  • 5.4 mg/kg组83例中34例(41%)发生≥3级药物相关治疗中出现的不良事件;6.4 mg/kg组39例中19例(49%)。
  • 药物相关间质性肺病或肺炎:5.4 mg/kg组7例(8%)均为1或2级;6.4 mg/kg组5例(13%),其中1例为5级。

核心结论

  • 作者认为,有前景的抗肿瘤活性和有利的安全性支持德曲妥珠单抗5.4 mg/kg作为经治HER2阳性转移性结直肠癌患者(包括RAS突变、既往抗HER2治疗或两者兼有)的最佳单药剂量。

研究设计与样本

  • DESTINY-CRC02为多中心、随机、两阶段、两臂2期研究,在澳大利亚、比利时、法国、意大利、日本、韩国、西班牙、中国台湾、英国和美国的53家研究医院和医疗中心进行。
  • 纳入年龄≥18岁或≥20岁(依地区而定)、经治的病理学证实不可切除、复发或转移性HER2阳性、RAS野生型或突变型结直肠癌患者,要求ECOG体力状态评分0或1,且既往接受过化疗,并在临床有指征时接受过抗EGFR、抗VEGF或抗PD-L1治疗。
  • 第一阶段患者按1:1随机分配接受5.4 mg/kg或6.4 mg/kg德曲妥珠单抗静脉给药,每21天一次,分层因素为ECOG体力状态、HER2状态和RAS状态;第二阶段患者仅分配至5.4 mg/kg治疗组。
  • 主要终点为盲法独立中心审查确认的客观缓解率,在全分析集(所有被分配治疗的患者)中评估;安全性在所有至少接受一剂研究药物的患者中评估。
  • 2021年3月5日至2022年3月29日期间,中心筛选135例患者,其中122例入组;第一阶段每组各40例随机分配至5.4 mg/kg和6.4 mg/kg组,第二阶段额外42例入组5.4 mg/kg组。

主要发现

  • 5.4 mg/kg组确认客观缓解率为37.8%(31/82,95%CI 27.3-49.2),6.4 mg/kg组为27.5%(11/40,95%CI 14.6-43.9)。
  • 5.4 mg/kg组83例中34例(41%)发生≥3级药物相关治疗中出现的不良事件,6.4 mg/kg组39例中19例(49%)。
  • 5.4 mg/kg组最常见的≥3级药物相关治疗中出现的不良事件为中性粒细胞计数降低13/83(16%)、贫血6/83(7%)、恶心6/83(7%)、白细胞计数降低5/83(6%);6.4 mg/kg组为中性粒细胞计数降低10/39(26%)、贫血8/39(21%)、血小板计数降低4/39(10%)、白细胞计数降低4/39(10%)。
  • 药物相关严重不良事件在5.4 mg/kg组83例中发生11例(13%),6.4 mg/kg组39例中发生6例(15%);5.4 mg/kg组最常见为恶心3例(4%),6.4 mg/kg组最常见为疲乏2例(5%)、中性粒细胞减少2例(5%)、血小板减少2例(5%)。
  • 药物相关治疗中出现的不良事件相关死亡在5.4 mg/kg组发生1例(1%)(归因于肝衰竭);裁定的药物相关间质性肺病或肺炎事件在5.4 mg/kg组7例(8%)均为1或2级,6.4 mg/kg组5例(13%)中4例为1或2级、1例为5级。

关键数值与推荐

  • 5.4 mg/kg组确认客观缓解率37.8%(31/82,95%CI 27.3-49.2),6.4 mg/kg组27.5%(11/40,95%CI 14.6-43.9)。
  • 5.4 mg/kg组随访中位时间8.9个月(IQR 6.7-10.5),6.4 mg/kg组10.3个月(IQR 5.9-12.7)。
  • 5.4 mg/kg组≥3级药物相关治疗中出现的不良事件34/83(41%),6.4 mg/kg组19/39(49%)。
  • 5.4 mg/kg组药物相关严重不良事件11/83(13%),6.4 mg/kg组6/39(15%)。
  • 5.4 mg/kg组药物相关间质性肺病或肺炎7/83(8%)均为1或2级,6.4 mg/kg组5/39(13%)中1例为5级。

临床怎么用

  • 作者认为,有前景的抗肿瘤活性和有利的安全性支持德曲妥珠单抗5.4 mg/kg作为经治HER2阳性转移性结直肠癌患者(包括RAS突变、既往抗HER2治疗或两者兼有)的最佳单药剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trastuzumab deruxtecan has shown encouraging activity in patients with treatment-refractory HER2-positive, RAS wild-type and BRAF wild-type metastatic colorectal cancer. Dose optimisation and further antitumour assessments in patients with RAS mutations and those with previous anti-HER2 therapy are warranted. We aimed to evaluate two doses of trastuzumab deruxtecan (5·4 mg/kg and 6·4 mg/kg) to establish the recommended dose in patients with pretreated HER2-positive, RAS wild-type or mutant metastatic colorectal cancer. METHODS: DESTINY-CRC02 was a multicentre, randomised, two-stage, two-arm, phase 2 study done in 53 research hospitals and medical centres in Australia, Belgium, France, Italy, Japan, South Korea, Spain, Taiwan, the UK, and the USA. Eligible patients were aged 18 years and older or 20 years and older (depending on region) with pretreated pathologically documented, unresectable, recurrent, or metastatic HER2-positive, and RAS wild-type or mutant colorectal cancer. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and have received previous chemotherapy, and anti-EGFR, anti-VEGF, or anti-PD-L1 therapy, if clinically indicated. In stage 1, patients were randomly assigned (1:1), via a secure interactive response technology system, to receive 5·4 mg/kg or 6·4 mg/kg trastuzumab deruxtecan administered intravenously every 21 days. Stratification factors were ECOG performance status, HER2 status, and RAS status. In stage 2, patients were assigned into the 5·4 mg/kg treatment group only. The primary endpoint was confirmed objective response rate by blinded independent central review, assessed in all patients for whom treatment was assigned (full analysis set). Safety was assessed in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT04744831, and is ongoing (not recruiting). FINDINGS: Between March 5, 2021, and March 29, 2022, 135 patients were centrally screened, 122 of whom were enrolled. In stage 1, 40 patients each were randomly assigned to receive trastuzumab deruxtecan 5·4 mg/kg and 6·4 mg/kg. In stage 2, an additional 42 patients were enrolled in the 5·4 mg/kg group. 64 (52%) participants were male and 58 (48%) were female. The median duration of follow-up was 8·9 months (IQR 6·7-10·5) in the 5·4 mg/kg group and 10·3 months (5·9-12·7) in the 6·4 mg/kg group. The confirmed objective response rate by blinded independent central review was 37·8% (31/82 [95% CI 27·3-49·2]) in the 5·4 mg/kg group and 27·5% (11/40 [14·6-43·9]) in the 6·4 mg/kg group. 34 (41%) of 83 patients in the 5·4 mg/kg group and 19 (49%) of 39 in the 6·4 mg/kg group had grade 3 or worse drug-related treatment-emergent adverse events. The most common grade 3 or worse drug-related treatment-emergent adverse events were neutrophil count decreased (13 [16%] of 83 patients), anaemia (six [7%]), nausea (six [7%]), and white blood cell count decreased (five [6%]) in the 5·4 mg/kg group; and were neutrophil count decreased (10 [26%] of 39 patients), anaemia (eight [21%]), platelet count decreased (four [10%]), and white blood cell count decreased (four [10%]) in the 6·4 mg/kg group. Drug-related serious adverse events occurred in 11 (13%) of 83 patients in the 5·4 mg/kg group and six (15%) of 39 patients in the 6·4 mg/kg group; the most common in the 5·4 mg/kg group was nausea (three [4%] patients) and the most common in the 6·4 mg/kg group were fatigue (two [5%] patients), neutropenia (two [5%]), and thrombocytopenia (two [5%]). A drug-related treatment-emergent adverse event related to death occurred in one (1%) patient in the 5·4 mg/kg group (due to hepatic failure). Adjudicated drug-related interstitial lung disease or pneumonitis events were observed in seven (8%) patients in the 5·4 mg/kg group (all grade 1 or 2) and in five (13%) patients in the 6·4 mg/kg group (four grade 1 or 2; one grade 5). INTERPRETATION: The promising antitumour activity and favourable safety profile support trastuzumab deruxtecan 5·4 mg/kg as the optimal single-agent dose for patients with pretreated HER2-positive metastatic colorectal cancer, including those with RAS mutations, previous anti-HER2 therapy, or both. FUNDING: Daiichi Sankyo and AstraZeneca.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Raghav K, Siena S, Takashima A, et al. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol. 2024. PMID: 39116902. doi:10.1016/S1470-2045(24)00380-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。